WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018081437) USE OF BETA-CATENIN AS A BIOMARKER FOR TREATING CANCERS USING ANTI-DKK-1 ANTIBODY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/081437 International Application No.: PCT/US2017/058555
Publication Date: 03.05.2018 International Filing Date: 26.10.2017
IPC:
A61K 39/395 (2006.01) ,A61K 31/337 (2006.01) ,C07K 16/18 (2006.01) ,C12Q 1/6886 (2018.01) ,A61P 35/00 (2006.01)
Applicants: LEAP THERAPEUTICS, INC.[US/US]; 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141, US
Inventors: KAGEY, Michael, H.; US
SIRARD, Cynthia, A.; US
Agent: ABELLEIRA, Susan, M.; US
AKHIEZER, Alexander; US
BLOUNT, Jannifer, V.; US
CAI, Mi; US
CHOI, Philip, S.; US
Priority Data:
62/413,19826.10.2016US
Title (EN) USE OF BETA-CATENIN AS A BIOMARKER FOR TREATING CANCERS USING ANTI-DKK-1 ANTIBODY
(FR) UTILISATION DE LA BÊTA-CATÉNINE EN TANT QUE BIOMARQUEUR POUR TRAITER DES CANCERS À L'AIDE D'UN ANTICORPS ANTI-DKK-1
Abstract:
(EN) A method of treating a cancer in a subject in need thereof is disclosed. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. The method comprises administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject is determined to have a constitutively activating mutation of the beta-catenin protein.
(FR) L'invention concerne une méthode permettant de traiter un cancer chez un patient nécessitant un tel traitement. Le cancer peut être un cancer de l'œsophage, un cancer de l'utérus, un cancer du foie, ou un cholangiocarcinome. Le procédé comprend l'administration au sujet d'une quantité efficace d'un anticorps anti-Dkk-1 ou d'un fragment de liaison à l'antigène de celui-ci, le sujet étant déterminé comme ayant une mutation d'activation constitutive de la protéine de bêta-caténine.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)